{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T19:37:57Z","timestamp":1793993877929,"version":"4.8.0"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,12,13]],"date-time":"2023-12-13T00:00:00Z","timestamp":1702425600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec><jats:title>Background\/Objective<\/jats:title><jats:p>Neurofilament light chain (NfL) has been proposed as a biomarker reflecting disease severity and therapy response in children with spinal muscular atrophy type 1 and 2 (SMA1 and 2). The objective of this study was to examine how serum NfL changes after gene replacement therapy (GRT) with onasemnogene abeparvovec-xioi.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We measured NfL in serum probes from 19 patients (10 SMA 1 and 6 SMA 2; 15 previously treated with nusinersen or risdiplam; 12 male) before and at variable time points after GRT. These values were related to motor scores (CHOP-Intend, HFMSE and RULM).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Median age at GRT was 19 months (range 2\u201346 months). Median NfL of all patients before GRT was 39 pg\/ml (range 0\u2013663 pg\/ml; normal values &amp;lt;25 pg\/ml), increased significantly to 297 pg\/ml (range 61\u20131,696 pg\/ml; p&amp;lt;0,002) 1 month after GRT, and decreased to 49 pg\/ml (range 24\u2013151 pg\/ml) after 6 months. Subjects pre-treated with nusinersen or risdiplam had lower baseline NfL levels than na\u00efve patients (p&amp;lt;0,005), but absolute increases of NfL were similar in both groups. While motor scores were improved in 14 out of 18 SMA patients (78%) 6 months after GRT NfL values differed not significantly from those measured at baseline (p = 0,959).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Serum NfL showed a paradoxical transient increase after GRT in both, pre-treated and na\u00efve patients, which may reflect an immunological reaction in the CNS related to transfection of neuronal cells by AAV9. The clinical meaning of this increase should be assessed in future studies. Our findings encourage regular monitoring of NfL in OA treated patients.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fneur.2023.1269406","type":"journal-article","created":{"date-parts":[[2023,12,13]],"date-time":"2023-12-13T12:51:03Z","timestamp":1702471863000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":15,"title":["Paradoxical increase of neurofilaments in SMA patients treated with onasemnogene abeparvovec-xioi"],"prefix":"10.3389","volume":"14","author":[{"given":"Marina","family":"Flotats-Bastardas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Bitzan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Grell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyriakos","family":"Martakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedikt","family":"Winter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Zemlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia D.","family":"Wurster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeljko","family":"Uzelac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Wei\u00df","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Hahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,12,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.1016\/S0140-6736(08)60921-6","article-title":"Spinal muscular atrophy","volume":"371","author":"Lunn","year":"2008","journal-title":"Lancet."},{"key":"B2","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","article-title":"A Identification and characterization of a spinal muscular atrophy-determining gene","volume":"80","author":"Lefebvre","year":"1995","journal-title":"Cell."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"A nusinersen versus sham control in infantile-onset spinal muscular atrophy","volume":"377","author":"Finkel","year":"2017","journal-title":"New Engl J Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","article-title":"a single-dose gene-replacement therapy for spinal muscular atrophy","volume":"377","author":"Mendell","year":"2017","journal-title":"New Engl J Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1056\/NEJMoa2009965","volume":"384","author":"Baranello","year":"2021","journal-title":"a Risdiplam in Type 1 Spinal Muscular Atrophy n Engl J Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1136\/jnnp-2018-320106","article-title":"Neurofilament light chain as a biomarker in neurological disorders","volume":"90","author":"Gaetani","year":"2019","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B7","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1136\/jnnp-2018-318704","article-title":"a Neurofilament light chain in serum for the diagnosis of amyotrophic lateral sclerosis","volume":"90","author":"Verde","year":"2019","journal-title":"J Neurol Neurosurg Psychiatr."},{"key":"B8","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1002\/acn3.51449","article-title":"A Serum neurofilament light chain in pediatric spinal muscular atrophy patients and healthy children","volume":"8","author":"Nitz","year":"2021","journal-title":"Annal Clinic Translat Neurol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.omtm.2021.10.011","article-title":"A implications of circulating neurofilaments for spinal muscular atrophy treatment early in life: a case series","volume":"23","author":"Alves","year":"2021","journal-title":"Mol Therapy Methods Clinic Develop."},{"key":"B10","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1002\/acn3.779","article-title":"A Neurofilament as a potential biomarker for spinal muscular atrophy","volume":"3","author":"Darras","year":"2019","journal-title":"Annal Clinic Translat Neurol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1756286419846058","DOI":"10.1177\/1756286419846058","article-title":"A Neurochemical markers in CSF of adolescent and adult SMA patients undergoing nusinersen treatment","volume":"12","author":"Wurster","year":"2019","journal-title":"Therapeutic Adv Neurologic Disord."},{"key":"B12","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s00415-019-09547-y","article-title":"A neurofilament light chain in serum of adolescent and adult SMA patients under treatment with nusinersen","volume":"267","author":"Wurster","year":"2020","journal-title":"J Neurol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1007\/s40261-021-01071-0","article-title":"A cerebrospinal fluid and clinical profiles in adult type 2-3 spinal muscular atrophy patients treated with nusinersen: an 18-month single-centre","volume":"41","author":"Milella","year":"2021","journal-title":"Experien Clinic Drug Investigat."},{"key":"B14","doi-asserted-by":"publisher","first-page":"117727192110356","DOI":"10.1177\/11772719211035643","article-title":"Update on biomarkers in spinal muscular atrophy","volume":"16","author":"Pino","year":"2021","journal-title":"Biomark Insights."},{"key":"B15","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/s00415-019-09389-8","article-title":"NFL is a marker of treatment response in children with SMA treated with nusinersen","volume":"19","author":"Olsson","year":"2019","journal-title":"J Neurol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s13023-019-0998-4","article-title":"a SMArtCARE\u2014a platform to collect real-life outcome data of patients with spinal muscular atrophy Orphanet","volume":"14","author":"Pechmann","year":"2019","journal-title":"J Rare Dis"},{"key":"B17","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1007\/s00115-020-00919-8","article-title":"A [Recommendations for gene therapy of spinal muscular atrophy with onasemnogene abeparvovec-AVXS-101 : consensus paper of the German representatives of the Society for Pediatric Neurology (GNP) and the German treatment centers with collaboration of the medical scientific advisory board of the German Society for Muscular Diseases (DGM)]","volume":"91","author":"Ziegler","year":"2020"},{"key":"B18","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1097\/PEP.0b013e318181ae96","article-title":"The test of infant motor performance: reliability in spinal muscular atrophy type I","volume":"20","author":"Finkel","year":"2008","journal-title":"Pediatr Phys Ther Fall."},{"key":"B19","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.nmd.2007.05.009","article-title":"An expanded version of the Hammersmith Functional Motor Scale for SMA II and III patients","volume":"17","author":"O'Hagen","year":"2007","journal-title":"Neuromuscul Disord."},{"key":"B20","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1002\/mus.25430","article-title":"A revised upper limb module for spinal muscular atrophy: development of a new module","volume":"55","author":"Mazzone","year":"2017","journal-title":"Muscle Nerve."},{"key":"B21","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s12883-017-0790-9","article-title":"A Content validity and clinical meaningfulness of the HFMSE in spinal muscular atrophy","volume":"17","author":"Pera","year":"2017","journal-title":"BMC Neurol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"e12140","DOI":"10.1371\/journal.pone.0012140","article-title":"A SMA CARNI-VAL trial part I: double-blind, randomized, placebo-controlled trial of L-carnitine and valproic acid in spinal muscular atrophy","volume":"5","author":"Swoboda","year":"2010","journal-title":"PLoS One."},{"key":"B23","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1038\/nbt.1641","article-title":"A Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations","volume":"28","author":"Rissin","year":"2010","journal-title":"Nat biotechnol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1177\/2211068215589580","article-title":"A Simoa HD-1 analyzer: a novel fully automated digital immunoassay analyzer with single-molecule sensitivity and multiplexing","volume":"21","author":"Wilson","year":"2016","journal-title":"J Lab Automation."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1002\/acn3.51355","article-title":"A Comparison of Simoa(TM) and Ella(TM) to assess serum neurofilament-light chain in multiple sclerosis","volume":"8","author":"Gauthier","year":"2021","journal-title":"Annals Clinic Translat Neurol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.nmd.2019.09.007","article-title":"A Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study","volume":"29","author":"De Vivo","year":"2019","journal-title":"Neuromuscul Disord."},{"key":"B27","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1136\/jnnp-2018-320033","article-title":"Neurofilaments and tau in CSF in an infant with SMA type 1 treated with nusinersen","volume":"9","author":"Winter","year":"2019","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B28","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S2352-4642(21)00287-X","article-title":"A Gene replacement therapy with onasemnogene abeparvovec in children with spinal muscular atrophy aged 24 months or younger and bodyweight up to 15 kg: an observational cohort study","volume":"6","author":"Wei\u00df","year":"2022","journal-title":"The Lancet Child Adolescent Health."},{"key":"B29","unstructured":"2023"},{"key":"B30","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1089\/hum.2021.255","article-title":"A single-dose intrathecal dorsal root ganglia toxicity of Onasemnogene Abeparvovec in Cynomolgus monkeys","volume":"33","author":"Tukov","year":"2022","journal-title":"Hum Gene Ther."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2023.1269406\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,13]],"date-time":"2023-12-13T12:51:12Z","timestamp":1702471872000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2023.1269406\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,13]]},"references-count":30,"alternative-id":["10.3389\/fneur.2023.1269406"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2023.1269406","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,13]]},"article-number":"1269406"}}